Assessment of efficacy of 5% topical amlexanox and 0.1% topical triamcinolone acetonide in management of recurrent aphthous stomatitis

Kavita, Kumari; Singh, Rohit; Singh, Rajendra; Gonuguntla, Sudhir; Luke, Alexander Maniangat; Jois, Harshvardhan Shridhar

doi:10.4103/jpbs.jpbs_133_20

Cited by 8 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Пацієнтам, у яких визначають окремі епізоди появи афт, що тривають лише кілька днів, буде достатньо застосування місцевого знеболювання, спрямованого на зменшення інтенсивності больових відчуттів, застосування засобів для прискорення епітелізації афт і запобігання вторинній інфекції [22]. Раціональним є використання антисептиків для полоскання порожнини рота, протизапальної терапії, нестероїдних протизапальних паст [12,21,24,27].…”

Section: а 3а 2в 3вunclassified

“…Обов'язковий етап -професійна гігієна, усунення травмувальних факторів і санація хронічних вогнищ інфекцій [26]. Рекомендовано використовувати м'яку зубну щітку, зубну пасту, що не містить лаурилсульфат натрію, а також рідину для полоскання рота без спирту [16,24].…”

Section: а 3а 2в 3вunclassified

See 1 more Smart Citation

Etiopathogenetic features of recurrent aphthous stomatitis: modern approaches to prevention and treatment

Hanchev¹,

Кокарь²

2023

ZMJ

View full text Add to dashboard Cite

Recurrent aphthous stomatitis (RAS) is an inflammatory disease of the oral mucosa, which has a chronic course with periods of remission and exacerbations. RAS requires adequate diagnosis for the purposes of properly treating. The study on RAS remains relevant over many years and continues to be a priority in modern dentistry. The aim of the work is to analyze the information in the professional literature on pathogenetic variants of RAS and approaches to its treatment and prevention. Despite the variety of studies, the etiology and pathogenesis of the disease remain the subject of numerous discussions. This article provides a review of current research on the main etiopathogenetic mechanisms of the disease development and progression, specifies current recommendations for therapeutic approaches to treatment and prevention. Conclusions. To date, there is no definitive therapeutic tactic for recurrent aphthous stomatitis, so it is advisable to systematize and study methods for the prevention and treatment of this pathology, including pain relief, acceleration of ulcer healing and reduction of its episode frequency and severity. Considering the etiopathogenetic variant of the disease development (metabolic disorders, stress, allergies, etc.), preventive measures should be comprehensive and include oral hygiene, a sparing diet, multivitamin and micro-, macroelement complexes, etc.

show abstract

Section: а 3а 2в 3вunclassified

Etiopathogenetic features of recurrent aphthous stomatitis: modern approaches to prevention and treatment

Hanchev¹,

Кокарь²

2023

ZMJ

View full text Add to dashboard Cite

show abstract

“…The goal of therapy includes pain control, suppression of the inflammatory response, reduction of recurrence frequency, reduction of ulcer border, and avoiding harmful effects of systemic treatments. RAU treatment includes topical and systemic drugs such as corticosteroids, antiseptics, and antibacterials, which are used singly or in varied combinations [ 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Formulation and Evaluation of Prednisolone Sodium Metazoate-Loaded Mucoadhesive Quatsomal Gel for Local Treatment of Recurrent Aphthous Ulcers: Optimization, In Vitro, Ex Vivo, and In Vivo Studies

et al. 2023

View full text Add to dashboard Cite

This study aims to formulate a buccal mucoadhesive gel containing prednisolone sodium metazoate-loaded quatsomes for efficient localized therapy of recurrent aphthous ulcers. Quatsomes were prepared using a varied concentration of quaternary ammonium surfactants (QAS) and cholesterol (CHO). A 23 factorial design was conducted to address the impact of independent variables QAS type (X1), QAS to CHO molar ratio (X2), and sonication time (X3). The dependent variables were particle size (PS; Y1), polydispersity index (PDI; Y2), zeta potential (ZP; Y3), entrapment efficiency percent (EE%; Y4) and percent of drug released after 6 h (Q6%: Y5). Then, the selected quatsomes formula was incorporated into different gel bases to prepare an optimized mucoadhesive gel to be evaluated via in vivo study. The PS of the developed quatsomes ranged from 69.47 ± 0.41 to 113.28 ± 0.79 nm, the PDI from 0.207 ± 0.004 to 0.328 ± 0.004, ZP from 45.15 ± 0.19 to 68.1 ± 0.54 mV, EE% from 79.62 ± 1.44 to 98.60% ± 1.22 and Q6% from 58.39 ± 1.75 to 94.42% ± 2.15. The quatsomal mucoadhesive gel showed rapid recovery of ulcers, which was confirmed by the histological study and the evaluation of inflammatory biomarkers. These results assured the capability of the developed quatsomal mucoadhesive gel to be a promising formulation for treating buccal diseases.

show abstract

Treatment Options in Pediatric Behçet’s Disease

2023

View full text Add to dashboard Cite

Behçet’s disease is a rare and poorly understood vasculitis affecting blood vessels of all types and sizes. Uveitis and oral and genital ulcers represent the typical clinical triad. Populations along the ancient trading route connecting the Mediterranean basin with the Middle and Far East are most affected. Up to a quarter of the cases has a pediatric onset, typically around puberty. The aim of the treatment is early intervention to control inflammation, with symptom relief and prevention of relapses, damage, and complications. The heterogeneous clinical presentation often requires a multidisciplinary and tailored approach. Ocular, neurological, gastrointestinal, and vascular involvement is associated with a worse prognosis and needs more aggressive treatments. In young patients with expected prolonged disease, treatment should also focus on preventive measures and lifestyle advice. In recent years, the pharmacological armamentarium has grown progressively, although only a limited number of drugs are currently authorized for pediatric use. Most evidence for these drugs still derives from adult studies and experience; these are prescribed as off-label medications and are only available as adult formulations. Corticosteroids frequently represent the mainstay for the management of the initial acute phases, but their potential serious adverse effects limit their use to short periods. Different conventional disease-modifying anti-rheumatic drugs have long been used. Many other biologic drugs targeting different cytokines such as interleukin-1, interleukin-6, and interleukin-17 and treatments with small molecules including the phosphodiesterase 4 and Janus kinase inhibitors are emerging as novel promising therapeutic agents. In recent years, a growing interest has developed around anti-tumor necrosis factor agents that have often proven to be effective in severe cases, especially in those with a gastrointestinal and ocular involvement.

show abstract

Assessment of efficacy of 5% topical amlexanox and 0.1% topical triamcinolone acetonide in management of recurrent aphthous stomatitis

Cited by 8 publications

References 11 publications

Etiopathogenetic features of recurrent aphthous stomatitis: modern approaches to prevention and treatment

Etiopathogenetic features of recurrent aphthous stomatitis: modern approaches to prevention and treatment

Formulation and Evaluation of Prednisolone Sodium Metazoate-Loaded Mucoadhesive Quatsomal Gel for Local Treatment of Recurrent Aphthous Ulcers: Optimization, In Vitro, Ex Vivo, and In Vivo Studies

Treatment Options in Pediatric Behçet’s Disease

Contact Info

Product

Resources

About